Europe Gene Editing Market (2024-2029)
The Europe Gene Editing Market was valued at $861.7 Million in 2024 and projected to reach to $1445.2 Million by 2029, representing a compound annual growth rate of 10.9%. Europe's gene editing market is poised for sustained expansion, driven by regulatory clarity, healthcare infrastructure maturity, and substantial investment in biotechnology innovation.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Europe Gene Editing Market Trends and Insights
- This expansion reflects Europe's strong regulatory framework, advanced healthcare infrastructure, and significant investment in precision medicine and biotechnology innovation.
- Europe is positioning itself as a global leader in gene editing applications across therapeutic and research domains. The European market benefits from collaborative research initiatives, substantial public and private funding, and a growing number of clinical trials leveraging CRISPR and other gene-editing technologies.
- Europe's commitment to ethical standards and regulatory clarity has attracted both established pharmaceutical companies and emerging biotech firms to accelerate their gene-editing programs.
- The 10.9% compound annual growth rate underscores Europe's pivotal role in shaping the future of genetic medicine. Key European markets, including Germany, the United Kingdom, France, and Switzerland, are driving innovation through academic partnerships and commercial development.
- Europe's emphasis on personalized medicine and rare disease treatment is expected to sustain momentum through 2029, positioning the region as a critical hub for gene-editing breakthroughs and clinical applications..
Key Market Statistics
- CAGR (2024-2029) 10.9% CAGR
- Market Size, 2024 ~USD 861.7 Million
- Forecast, 2029 ~USD 1445.2 Million
- Geography Europe
Europe Gene Editing Market Overview
Market Valuation & Growth :
Europe's gene editing market is valued at $861.7 million in 2024, with a robust CAGR of 10.9% projected through 2029, reaching $1,445.2 million. This outpaces the global CAGR of 10.2%, positioning Europe as a high-growth region in precision medicine.
Regulatory Leadership :
Europe's advanced regulatory framework, including EMA oversight and GDPR compliance, establishes a gold standard for gene editing therapies. This creates competitive advantages for companies developing innovative treatments and attracts significant biotech investment across the continent.
Healthcare Infrastructure Excellence :
Europe's sophisticated healthcare systems, strong R&D capabilities, and substantial government funding for biotechnology innovation provide an ideal ecosystem for gene editing development. Leading research institutions and clinical trial infrastructure accelerate therapeutic advancement.
Precision Medicine Investment :
Significant European investment in precision medicine and personalized healthcare drives demand for gene editing solutions. Strategic partnerships between academic institutions, biotech firms, and pharmaceutical companies fuel market expansion and clinical applications.
Europe Gene Editing Market Dynamics
- The region's commitment to precision medicine and personalized treatment approaches creates strong demand for advanced gene editing technologies across therapeutic areas including oncology, rare genetic disorders, and immunotherapy. Key growth catalysts include increasing clinical trial approvals, expanding reimbursement pathways, and collaborative research initiatives across European nations.
- With leading biotech hubs in Germany, UK, and France, Europe is establishing itself as a global innovation center for gene editing applications, attracting talent and capital while advancing breakthrough therapies to market..
Related Ecosystem
Key Takeaways
- Europe's gene editing market is valued at $861.7 million in 2024 and is projected to reach $1,445.2 million by 2029, representing a 10.9% CAGR.
- Europe's robust regulatory framework and ethical standards have positioned the region as a trusted hub for gene-editing innovation and clinical development.
- Strong academic-industry partnerships and substantial public funding across Europe are accelerating the translation of gene-editing research into therapeutic applications.
- Europe's focus on rare disease treatment and personalized medicine is driving sustained market growth and attracting global biotech investment through 2029.
Gene Editing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | CROS & CDMOS (End User) |
| Forecast Period | 2024–2029 |
| Growth Rate | CAGR of 10.2% from 2024 to 2029 |
| Largest Segment | PRODUCTS (Offering) |
| Market Size Base Year (Billions) | ~USD 4.67 (2024) |
| Revenue Forecast (Billions) | ~USD 7.59 (2029) |
| Segments Covered | Offering, Type, Technique, Technology, Application, End User |
Europe Gene Editing Market Report Segmentation
6 segment dimensions are covered across the global market.
By Offering
- Products
- Services
By Type
- Cell Line Development & Engineering
- Gene Editing Kits
- Gene Editing Libraries
- Gene Editing Reagents
- Grna Synthesis & Vector Construction
- Library Construction & Screening
- Other Services
- Reagents & Consumables
- Software & Systems
By Technique
- Gene Silencing
- Knock-In
- Knock-Out
- Other Techniques
By Technology
- Antisense
- Base Editing
- Crispr
- Other Technologies
- Rnai
- Talens
- Zfns
By Application
- Cell Line Engineering
- Drug Discovery & Development
- Genome Editing
- Other Applications
By End User
- Academic & Research Institutes
- Cros & Cdmos
- Other End Users
- Pharmaceutical & Biotechnology Companies
EUROPE: GENE EDITING PRODUCTS MARKET, BY END USER, 2022–2029
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 265.8 | 256.8 | 269.1 | 299.4 | 333.7 | 371.9 | 415.1 | 464.3 | 11.5 |
| CROS & CDMOS | 120.7 | 118.6 | 126.2 | 142.6 | 161.4 | 182.6 | 206.6 | 234.4 | 13.2 |
| OTHER END USERS | 112.9 | 105.4 | 106.5 | 114.3 | 122.8 | 131.7 | 141.3 | 151.7 | 7.3 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 361.7 | 346.5 | 359.9 | 396.9 | 438.7 | 484.7 | 536.3 | 594.8 | 10.6 |
| TOTAL | 861 | 827.2 | 861.7 | 953.2 | 1056.6 | 1170.9 | 1299.3 | 1445.2 | 10.9 |
REST OF EUROPE: GENE EDITING SERVICES MARKET, BY END USER, 2022–2029
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 26.3 | 25.1 | 27.8 | 31.3 | 35.2 | 39.6 | 44.6 | 50.4 | 12.6 |
| CROS & CDMOS | 5.3 | 5.3 | 6.2 | 7.2 | 8.5 | 9.9 | 11.5 | 13.5 | 16.9 |
| OTHER END USERS | 14.7 | 13.5 | 14.4 | 15.6 | 16.9 | 18.2 | 19.7 | 21.3 | 8.1 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 38 | 35.9 | 39.3 | 43.7 | 48.6 | 54.1 | 60.2 | 67.2 | 11.3 |
| TOTAL | 84.3 | 79.8 | 87.7 | 97.7 | 109.1 | 121.8 | 136.1 | 152.4 | 11.7 |
Target Audience
- Pharmaceutical & Biotech Companies : Evaluate European market opportunities, competitive positioning, and regulatory pathways for gene editing therapeutics. Identify expansion strategies and partnership opportunities in high-growth European markets.
- Healthcare Investors & Venture Capital : Assess investment potential in European gene editing companies and biotech startups. Understand market growth trajectories, funding trends, and exit opportunities across the region.
- Medical Device & Diagnostic Manufacturers : Explore complementary opportunities in gene editing support technologies, diagnostics, and delivery systems. Identify partnerships and market entry strategies for European healthcare providers.
- Healthcare Policy & Regulatory Bodies : Understand market dynamics, clinical adoption rates, and reimbursement trends to inform policy development. Support evidence-based decision-making on gene editing regulation and healthcare resource allocation.
- Academic & Research Institutions : Benchmark European research capabilities, identify collaboration opportunities, and understand commercialization pathways. Support strategic planning for gene editing research programs and clinical translation initiatives.
Key Companies in the Europe Gene Editing Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| EPPENDORF AG | Germany | Private Company | Liquid handling (pipettes, dispensers, automated systems),Separation & instrumentation (centrifuges, PCR cyclers, ULT freezers),Consumables (tubes, tips, plates, single-use bioreactors), |
| ILLUMINA INC | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables, |
| CALYXT | United States | Public Company | RTDS / Trait Machine platform services,Licensed gene-edited traits (royalties and access fees),Collaborative R&D and proof-of-concept projects, |
| MAXCYTE, INC | United States | Public Company | ExPERT GTx and VLx (therapeutic-scale instruments),ExPERT STx and ATx (discovery and development instruments),Disposable processing assemblies and consumables, |
| BECKMAN COULTER | United States | Private Company | Clinical diagnostics analyzers and reagents (chemistry, immunoassay, hematology, urinalysis, hemostasis, clinical flow cytometry),Research and discovery systems (flow cytometry, centrifugation, liquid handling, genomics and single-cell tools),Industrial and particle characterization instruments, |
| TAKEDA PHARMACEUTICAL COMPANY | Japan | Public Company | Gastroenterology (Entyvio, Takecab/Vocinti, EOHILIA),Rare Diseases & Plasma-Derived Therapies (Takhzyro, Advate, ADZYNMA, Gammagard, Hyqvia, Cuvitru, Flexbumin),Oncology (Adcetris, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, Leuplin/Enantone), |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and single-use solutions),Life Sciences (tools, genomics, and imaging),Diagnostics (clinical instruments and consumables), |
| REVVITY, INC. | United States | Public Company | Diagnostics assays and instruments (prenatal, neonatal, infectious disease, autoimmunity),Life science reagents and consumables (immunology, cell biology, genomics),Instruments, imaging, and detection platforms, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| MERCK KGAA | Germany | Public Company | Life Science (reagents, consumables, bioprocessing, CDMO/testing services),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, specialty gases, equipment), |
| GENSCRIPT | Hong Kong | Public Company | Life Science Services and Products,Biologics Development Services,Industrial Synthetic Biology Products, |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| LONZA | Switzerland | Public Company | Integrated Biologics,Advanced Synthesis (small molecules, ADCs, HPAPIs),Specialized Modalities (cell & gene, microbial, bioscience, mRNA), |
| SANGAMO THERAPEUTICS | United States | Public Company | Hemophilia A gene therapy collaborations (SB-525 / giroctocogene fitelparvovec),Fabry and other AAV gene therapy programs (ST-920 and related),Genetically modified cell therapy (TX200, kidney transplant), |
| PRECISION BIOSCIENCES | United States | Public Company | ARCUS platform collaborations and licensing,In vivo HBV and liver disease programs (PBGENE-HBV, iECURE-OTC),Neuromuscular and mitochondrial programs (PBGENE-DMD, PBGENE-3243), |
| CELLECTIS S.A. | France | Public Company | Allogeneic CAR-T for hematologic malignancies (BALLI-01, NatHaLi-01, ALPHA3),Gene therapy and non-hematologic oncology (TRAVERSE, Melanoma, other gene-editing programs),Platform technologies, collaborations, and other R&D-related revenue, |
| REGENERON PHARMACEUTICALS, INC. | United States | Public Company | EYLEA franchise (incl. 8 mg),Dupixent (atopic dermatitis, asthma, other type 2 diseases),Oncology (Libtayo and emerging bispecifics), |
| TAKARA BIO INC. | Japan | Private Company | Genetic and cellular research reagents,Instruments (PCR and cellular analysis devices),In vitro diagnostics (COVID-19 and related), |
EPPENDORF AG
Eppendorf AG is a German private company founded in 1945 that employs 4,358 people. The company specializes in laboratory equipment and life sciences solutions.
ILLUMINA INC
Illumina Inc. is a publicly traded U.S. company founded in 1998 with 8,625 employees. It is a leading provider of DNA sequencing and genetic analysis technologies.
CALYXT
Calyxt is a publicly traded U.S. company founded in 2010 with 118 employees. The company focuses on plant biotechnology and gene-edited crop development.
MAXCYTE, INC
MaxCyte, Inc. is a publicly traded U.S. company founded in 1998 with 91 employees. It develops cell engineering technologies for therapeutic applications.
BECKMAN COULTER
Beckman Coulter is a private U.S. company founded in 1935 with 11,900 employees. It manufactures laboratory instruments and diagnostic equipment for life sciences research.
TAKEDA PHARMACEUTICAL COMPANY
Takeda Pharmaceutical Company is a publicly traded Japanese pharmaceutical company founded in 1781 with 47,029 employees. It is one of the world's largest pharmaceutical manufacturers.
DANAHER CORPORATION
Danaher Corporation is a publicly traded U.S. company founded in 1969 with 59,000 employees. It operates a diversified portfolio of businesses in diagnostics, life sciences, and environmental solutions.
REVVITY, INC.
Revvity, Inc. is a publicly traded U.S. company founded in 1937 with 11,000 employees. It provides analytical technologies and solutions for life sciences and diagnostics.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a publicly traded U.S. company founded in 1956 with 125,000 employees. It is a global leader in serving science with laboratory equipment, reagents, and analytical instruments.
MERCK KGAA
Merck KGaA is a publicly traded German company founded in 1668 with 59,077 employees. It operates in pharmaceuticals, life sciences, and performance materials sectors.
GENSCRIPT
GenScript is a publicly traded company based in Hong Kong, founded in 2002 with 6,165 employees. It provides biotechnology services including gene synthesis, protein production, and antibody development.
AGILENT TECHNOLOGIES, INC.
Agilent Technologies, Inc. is a publicly traded U.S. company founded in 1999 with 18,000 employees. It manufactures analytical instruments and laboratory equipment for life sciences and diagnostics.
LONZA
Lonza is a publicly traded Swiss company founded in 1897 with 20,000 employees. It provides contract manufacturing and life sciences solutions for pharmaceuticals and biotechnology.
SANGAMO THERAPEUTICS
Sangamo Therapeutics is a publicly traded U.S. company founded in 1995 with 142 employees. It develops gene therapy and cell therapy treatments using zinc finger protein technology.
PRECISION BIOSCIENCES
Precision Biosciences is a publicly traded U.S. company founded in 2006 with 66 employees. It develops gene-editing therapies using its proprietary genome editing platform.
CELLECTIS S.A.
Cellectis S.A. is a publicly traded French company founded in 1999 with 227 employees. It develops immunotherapy treatments using gene-edited cell technologies.
REGENERON PHARMACEUTICALS, INC.
Regeneron Pharmaceuticals, Inc. is a publicly traded U.S. company founded in 1988 with 15,343 employees. It discovers, develops, and commercializes medicines for serious medical conditions.
TAKARA BIO INC.
Takara Bio Inc. is a private Japanese company founded in 2002 with 1,779 employees. It develops and manufactures biotechnology products and services for life sciences research.
Countries within Europe - compare and drill down
| Country | 2025 size (native) |
|---|---|
| Germany | USD 198.7 Million |
| UK | USD 162.1 Million |
| France | USD 125.5 Million |
| Italy | USD 53.4 Million |
| Spain | USD 40.3 Million |
| Rest Of Europe | USD 153.3 Million |
Country market size visualization
Reasons to Buy this Report
- Regional Market Segmentation : Gain detailed insights into Europe's gene editing market dynamics, including country-level breakdowns for Germany, UK, France, Italy, Spain, and Rest of Europe. Understand regional variations in market size, growth rates, and therapeutic applications.
- Competitive Landscape Analysis : Identify leading gene editing companies, research institutions, and biotech firms operating across Europe. Analyze competitive positioning, market share, and strategic partnerships shaping the regional market.
- Regulatory & Reimbursement Insights : Understand Europe's unique regulatory environment, EMA approval pathways, and reimbursement mechanisms. Navigate compliance requirements and identify opportunities in this highly regulated but innovation-friendly market.
- Investment & Growth Opportunities : Discover high-potential market segments, emerging therapeutic applications, and geographic expansion opportunities. Identify funding trends and strategic investment areas driving European gene editing innovation.
- Strategic Decision Support : Make informed business decisions with comprehensive market data, forecasts, and trend analysis specific to Europe. Support market entry strategies, partnership development, and resource allocation planning.
Frequently asked questions
What is the current size of Europe's gene editing market?
Europe's gene editing market was valued at $861.7 million in 2024 and is expected to grow to $1,445.2 million by 2029.
What is the projected growth rate for Europe's gene editing market?
Europe's gene editing market is projected to grow at a compound annual growth rate (CAGR) of 10.9% from 2024 to 2029.
Which countries are leading Europe's gene editing market?
Germany, the United Kingdom, France, and Switzerland are among the leading markets in Europe, driven by strong research institutions, regulatory support, and biotech investment.
What factors are driving growth in Europe's gene editing market?
Key drivers include Europe's advanced healthcare infrastructure, robust regulatory framework, significant public and private funding, collaborative research initiatives, and growing clinical trials in precision medicine and rare disease treatment.
How does Europe's gene editing market compare to the global market?
Europe's 10.9% CAGR slightly exceeds the global CAGR of 10.2%, reflecting Europe's strong position in gene-editing innovation and clinical development through 2029.
RESEARCH METHODOLOGY
This study on the gene editing market employed secondary sources, directories, and databases to gather pertinent information. To gather and validate important qualitative and quantitative data and evaluate market growth prospects, in-depth interviews were conducted with many primary respondents including key industry participants, subject-matter experts (SMEs), C-level executives from key market players, and industry consultants. After estimating the gene editing market using several research strategies, the size of the final market was obtained by triangulating data from primary research.
Secondary Research
The secondary sources referred to for this research study include publications from government sources, such as the International Chromosome and Genome Society (ICGS), the National Human Genome Research Institute (NHGRI), the Asia Pacific Society of Human Genetics (APSHG), the Genetics Society of America (GSA), the European Society of Human Genetics (ESHG), Centers for Common Disease Genomics (CDDG), Centre for Cellular & Molecular Biology (CCMB) (India), and the Department of Biotechnology (DBT) (India). Secondary sources include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global gene editing market, which was validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global gene editing market scenario through secondary research. Several primary interviews were conducted with market experts from the supply side, such as C-level and D-level executives, operational managers, marketing & sales managers of key manufacturers, distributors, and channel partners of companies providing gene editing products and services; experts from the demand side, such as personnel from pharmaceutical & biotechnology companies, Academic & research institutes, and CROs & CDMOs. These interviews were conducted across six major regions, including North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the gene editing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Bottom-up Approach
- The key players in the industry and market have been identified through extensive secondary research.
- The revenues generated from the gene editing market business of leading players have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Top-down Approach
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.
Data Triangulation
To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
The gene editing market, as covered within the scope of this report, includes products, technologies, and services that facilitate genetic modifications across various applications. This encompasses reagents and consumables, as well as software and systems for planning, executing, and analyzing gene editing processes. Additionally, the report covers services that utilize gene editing technologies like CRISPR, TALEN, ZFN, and other methods such as Meganucleases, PiggyBac, and Prime Editing, applied in areas like cell line engineering, genome editing, drug discovery, clinical diagnostics, and xenotransplantation. These components serve end users, including pharmaceutical and biotechnology companies involved in therapeutic development, as well as academic and research institutes focused on scientific research.
Stakeholders
- Manufacturers and distributors of gene editing products and services
- Pharmaceutical and biotechnology companies
- Market research and consulting firms
- R&D centers
- Researchers and scientists
- Academic & research institutes
- CDMOs & CROs
- Biobanks
- Diagnostic companies.
Report Objectives
- To define, describe, segment, and forecast the gene editing market based on offerings, product type, product application, product technology, reagent & consumables technique, product end user, service type, service application, service end user and region
- To provide detailed information about the factors influencing market growth, such as drivers, restraints, opportunities, and challenges
- To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall gene editing market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments concerning six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa.
- To strategically profile the key players in the global gene editing market and comprehensively analyze their core competencies2 and market rankings.
- To track and analyze competitive developments, such as product launches, acquisitions, collaborations, expansions, and partnerships in the gene editing market.
- To profile the key players in the global gene editing market and comprehensively analyze their instruments, reagents, kits, consumables, and services portfolios, market positions, and core competencies
- To track and analyze competitive developments such as product & service launches, expansions, agreements, and collaborations in the gene editing market
- To benchmark players within the gene editing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and service strategy
Get the Full Gene Editing Market Report
Full forecast, segment splits, and company analysis for all Gene Editing Market.
- US Gene Editing Market
- Canada Gene Editing Market
- Germany Gene Editing Market
- France Gene Editing Market
- UK Gene Editing Market
- Italy Gene Editing Market
- Spain Gene Editing Market
- China Gene Editing Market
- Japan Gene Editing Market
- India Gene Editing Market
- South Korea Gene Editing Market
- Australia Gene Editing Market
- Brazil Gene Editing Market
- United Arab Emirates Gene Editing Market
- Rest Of Europe Gene Editing Market
- Rest Of Asia Pacific Gene Editing Market
- Rest Of Latin America Gene Editing Market
- Ksa Gene Editing Market
- Other GCC Countries Gene Editing Market
- UAE Gene Editing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
